CVRdatabase
Menu

Valeos Pharma A/S

Public limited companyCVR 39696614HolebyActive

Valeos Pharma A/S is a public limited company, based in Holeby, active in manufacture of pharmaceutical preparations, founded in 2018. Equity was negative at the end of 2025 (−DKK 6.7m). The company made a loss in both 2024 and 2025, most recently DKK 13.5m. 6 other companies in the database are registered at the same address.

Follow
PDF reportCompare

Key figures · financial year 2025

Gross profitDKK 976k+125.4% vs. 2024
Net profit−DKK 13.5m+20.4% vs. 2024
Equity−DKK 6.7m−198.3% vs. 2024
Employees21latest month from CVR

What has changed

calculated from recorded figures and dates

Financials: 2025 against 2024

  • The loss got smaller: from DKK 16.9m to DKK 13.5m (2024 → 2025).
  • Equity turned negative: −DKK 6.7m (2024 → 2025).

Employees

  • 2 more employees than a year earlier: 21 (07/2026) against 19 (07/2025).

Management and owners, last 24 months

  • New in management: Peter Frederik Andreasen (ceo, 26/05/2025) and Glenn Steven Nielsen (chair of the board, 17/06/2025).
  • Stepped down: Henrik Kristian Moltke (chair of the board, 17/06/2025) and Morten Larsen Snede (ceo, 26/05/2025).
  • New owners registered: A. Rosen Holding ApS (07/11/2024), MSG Capital APS (07/11/2024) and Kleingut ApS (07/11/2024).
  • No longer registered as owner: A. Rosen Holding ApS (06/11/2024), Henriksholm 2018 ApS (07/11/2024) and MSG Capital APS (06/11/2024) (+1).

Registrations, last 24 months

  • 01/01/2025: Industry changed to Manufacture of pharmaceutical preparations (212000)
  • 07/11/2024: Share capital changed from 621,224 DKK to 802,635 DKK

Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.

Financial statements

Financial years 2020–2025 · amounts in DKK thousand

Equity and net profit

−DKK 20m−DKK 15m−DKK 10m−DKK 5mDKK 0DKK 5mDKK 10mDKK 15m202020212022202320242025
EquityNet profit
Financial figures for Valeos Pharma A/S
202020212022202320242025Change
Revenuenot statednot statednot statednot statednot statednot stated–
Gross profit−1,277−3,379−6,489−5,839−3,847976+125.4%
Operating profit (EBIT)−1,979−7,413−13,380−17,231–−13,741–
Profit before tax−2,173−8,209−14,637−21,168−21,701−17,152+21%
Net profit−1,705−6,408−11,426−16,534−16,945−13,487+20.4%
Total assets22,24749,94557,32261,09558,14452,838−9.1%
Equity−1,41616,5325,106−8,4286,800−6,687−198.3%
Liabilities23,66433,40852,20869,52350,19057,203+14%
Cash and cash equivalents685,3590––––
Average number of employees27101819190%

Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2020, 2021, 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.

Download the figures as CSV · free with an account, amounts in whole DKK

−DKK 8m−DKK 6m−DKK 4m−DKK 2mDKK 0DKK 2m202020212022202320242025
Gross profitMedian, the industry (59 companies)

Signals from the financial statements

calculated from the 2025 figures

  • Negative equity

    Equity was −DKK 6.7m at the end of 2025.

    How is this calculated?

    Equity in the latest annual report is below zero.

  • Loss for 6 years in a row

    Net result has been negative in 2020–2025.

    How is this calculated?

    Net result is negative in the two or more latest annual reports in a row.

The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.

Annual reports

6 financial years
Annual reports for Valeos Pharma A/S
Financial yearPeriodPublishedFigures forDocuments
202501/01/2025 – 31/12/202513/07/2026The companyPDF not statedXBRL
202401/01/2024 – 31/12/202428/06/2025The companyPDFXBRL
202301/01/2023 – 31/12/202303/07/2024The companyPDFXBRL
202201/01/2022 – 31/12/202206/07/2023The companyPDFXBRL
202101/01/2021 – 31/12/202120/07/2022The companyPDFXBRL
202001/01/2020 – 31/12/202008/07/2021The companyPDFXBRL

The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.

Employees

monthly figures from CVR
051015202508/2309/2310/2311/2312/2301/2402/2403/2404/2405/2406/2407/2408/2409/2410/2411/2412/2401/2502/2503/2504/2505/2506/2507/2508/2509/2510/2511/2512/2501/2602/2603/2604/2605/2606/2607/26
Employees

Position in the industry

59 companies in the database

Comparison with the other companies in manufacture of pharmaceutical preparations based on the latest financial year.

Gross profitDKK 976kNo. 31 of 57
Better than 46% of the companies in the industry
Equity−DKK 6.7mNo. 51 of 59
Better than 14% of the companies in the industry
Number of employees21No. 22 of 59
Better than 64% of the companies in the industry

Industry median: gross profit DKK 2.8m, net profit −DKK 2.2m, equity DKK 5.2m, 10 employees.

DKK 266kDKK 8.3mDKK 258mDKK 8bnDKK 79.6bnHere
Distribution of gross profit for 34 companies in the industry (latest financial year, logarithmic scale). Amber bar: where this company sits.

Compared with similar companies

size, age and company form
Rank among similar companies
GroupGross profitEquity
Companies with 20–49 employees9,922 companies in the comparison
No. 9,467of 9,892
Better than 4%
No. 9,741of 9,922
Better than 2%
Companies that are between 5 and 14 years old33,688 companies in the comparison
No. 23,512of 33,588
Better than 30%
No. 33,203of 33,687
Better than 1%
All companies of type A/S18,025 companies in the comparison
No. 15,664of 17,786
Better than 12%
No. 17,730of 18,024
Better than 2%

The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.

Compare with the industry

Manufacture of pharmaceutical preparations
Gross profit
  1. Valeos Pharma A/SDKK 976k
  2. Novo Nordisk A/SDKK 250.3bn
  3. H. Lundbeck A/SDKK 20.4bn
Net profit
  1. Valeos Pharma A/S−DKK 13.5m
  2. Novo Nordisk A/SDKK 102.4bn
  3. H. Lundbeck A/SDKK 3.2bn
Equity
  1. Valeos Pharma A/S−DKK 6.7m
  2. Novo Nordisk A/SDKK 194bn
  3. H. Lundbeck A/SDKK 24.9bn
Employees
  1. Valeos Pharma A/S21
  2. Novo Nordisk A/S27,279
  3. H. Lundbeck A/S2,261

Latest financial year per company. Choose up to three companies from the largest in the industry.

Owners and group

from the Public Ownership Register
Owners
  • A. Rosen Holding ApS15%
  • MSG Capital APS50%
  • Kleingut ApS10%
Valeos Pharma A/S

Management

5 active registrations

Executive management

Executive management at Valeos Pharma A/S
NameRoleAppointed
Peter Frederik AndreasenCEO26/05/2025

Board of directors

Board of directors at Valeos Pharma A/S
NameRoleAppointed
Michael Halborg-BendtsenBoard member18/11/2019
Peter Frederik AndreasenBoard member11/10/2021
Kristian Schrøder Hart-HansenBoard member04/07/2022
Glenn Steven NielsenChair of the board17/06/2025
Founders
Peter Frederik Andreasen
Former management (13)
Former management at Valeos Pharma A/S
NameRoleAppointedResigned
Peter Frederik AndreasenCEO03/07/201805/10/2021
Glenn Steven NielsenChair of the board18/11/201914/04/2021
Totti Hannu Miikael VuosioBoard member18/11/201905/04/2021
Kristian Schrøder Hart-HansenBoard member05/04/202114/04/2021
Michael AndreasenBoard member05/04/202111/10/2021
Kristian Schrøder Hart-HansenChair of the board15/04/202103/07/2022
Glenn Steven NielsenBoard member15/04/202104/07/2022
Peter Frederik AndreasenDirector06/10/202122/11/2021
Birgitte Steen FrydlandCEO06/10/202107/03/2022
Farzad JahanshahiCEO07/03/202207/03/2022
Peter Frederik AndreasenCEO07/03/202212/02/2024
Henrik Kristian MoltkeChair of the board04/07/202217/06/2025
Morten Larsen SnedeCEO12/02/202426/05/2025

Signing rule: Selskabet tegnes af direktøren sammen med bestyrelsesformanden eller af den samlede bestyrelse.

Address and production units

1 active production units

Østervej 2
4960 Holeby

Lolland Municipality · Postcode 4960

Other companies at the address (6)

Production units
Production unitAddressEmployeesP number
Valeos Pharma A/SØstervej 2, 4960 Holeby191023762761

Purpose

Virksomhedens formål er at dyrke medicinsk cannabis og hermed beslægtede produkter og hermed beslægtet virksomhed

The purpose is quoted from the register in Danish.

Changes year by year

76 registered events
20261 changeaccounts 1
  • Annual report for 2025 published
20256 changesaccounts 1 · management 4 · industry 1
  • Annual report for 2024 published
  • Glenn Steven Nielsen appointed chair of the board
  • Henrik Kristian Moltke stepped down as chair of the board
  • Peter Frederik Andreasen appointed ceo
  • Morten Larsen Snede stepped down as ceo
  • Industry changed to Manufacture of pharmaceutical preparations (212000)
202415 changescapital 5 · ownership 7 · accounts 1 · management 2
  • Share capital changed from 621,224 DKK to 802,635 DKK
  • A. Rosen Holding ApS registered as owner (15%)
  • Kleingut ApS registered as owner (10%)
  • MSG Capital APS registered as owner (50%)
  • Henriksholm 2018 ApS is no longer registered as owner
  • A. Rosen Holding ApS is no longer registered as owner
  • MSG Capital APS is no longer registered as owner
  • Kleingut ApS is no longer registered as owner
  • Annual report for 2023 published
  • Share capital changed from 594,730 DKK to 621,224 DKK
  • Share capital changed from 568,236 DKK to 594,730 DKK
  • Morten Larsen Snede appointed ceo
  • Peter Frederik Andreasen stepped down as ceo
  • Share capital changed from 529,872 DKK to 568,236 DKK
  • Share capital changed from 526,691 DKK to 529,872 DKK
20232 changescapital 1 · accounts 1
  • Share capital changed from 514,811 DKK to 526,691 DKK
  • Annual report for 2022 published
202210 changesaccounts 1 · name 1 · management 8
  • Annual report for 2021 published
  • Name changed from Valeos A/S to Valeos Pharma A/S
  • Henrik Kristian Moltke appointed chair of the board
  • Kristian Schrøder Hart-Hansen appointed board member
  • Glenn Steven Nielsen stepped down as board member
  • Kristian Schrøder Hart-Hansen stepped down as chair of the board
  • Farzad Jahanshahi appointed ceo
  • Farzad Jahanshahi stepped down as ceo
  • Peter Frederik Andreasen appointed ceo
  • Birgitte Steen Frydland stepped down as ceo
202125 changescapital 3 · management 13 · accounts 1 · ownership 8
  • Share capital changed from 481,328 DKK to 514,811 DKK
  • Peter Frederik Andreasen stepped down as director
  • Peter Frederik Andreasen appointed board member
  • Michael Andreasen stepped down as board member
  • Birgitte Steen Frydland appointed ceo
  • Peter Frederik Andreasen appointed director
  • Peter Frederik Andreasen stepped down as ceo
  • Annual report for 2020 published
  • Share capital changed from 432,653 DKK to 481,328 DKK
  • A. Rosen Holding ApS registered as owner (10%)
  • Henriksholm 2018 ApS registered as owner (5%)
  • MSG Capital APS registered as owner (50%)
  • Kleingut ApS registered as owner (15%)
  • Novosato Holding ApS is no longer registered as owner
  • Kleingut ApS is no longer registered as owner
  • A. Rosen Holding ApS is no longer registered as owner
  • MSG Capital APS is no longer registered as owner
  • Share capital changed from 400,000 DKK to 432,653 DKK
  • Glenn Steven Nielsen appointed board member
  • Kristian Schrøder Hart-Hansen appointed chair of the board
  • Kristian Schrøder Hart-Hansen stepped down as board member
  • Glenn Steven Nielsen stepped down as chair of the board
  • Michael Andreasen appointed board member
  • Kristian Schrøder Hart-Hansen appointed board member
  • Totti Hannu Miikael Vuosio stepped down as board member
20207 changesownership 5 · name 1 · capital 1
  • Novosato Holding ApS registered as owner (20%)
  • Totti Hannu Miikael Vuosio is no longer registered as owner
  • Kleingut ApS registered as owner (10%)
  • Peter Frederik Andreasen is no longer registered as owner
  • A. Rosen Holding ApS registered as owner (10%)
  • Name changed from Valeos ApS to Valeos A/S
  • Share capital changed from 125,000 DKK to 400,000 DKK
20197 changesname 1 · capital 1 · management 3 · ownership 2
  • Name changed from Valeos IVS to Valeos ApS
  • Share capital changed from 10,000 DKK to 125,000 DKK
  • Michael Halborg-Bendtsen appointed board member
  • Glenn Steven Nielsen appointed chair of the board
  • Totti Hannu Miikael Vuosio appointed board member
  • MSG Capital APS registered as owner (50%)
  • Totti Hannu Miikael Vuosio registered as owner (20%)
20183 changesfounded 1 · management 1 · ownership 1
  • Registered as Valeos IVS
  • Peter Frederik Andreasen appointed ceo
  • Peter Frederik Andreasen registered as owner (10%)

Related companies

Same industry in Lolland

See all →

Same people in management

Largest in the industry

See all →

Source and updates

The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.

View in CVRReport a correction